Anti‐tumor efficacy of human anti‐c‐met CAR‐T cells against papillary renal cell carcinoma in an orthotopic model
J Mori, K Adachi, Y Sakoda, T Sasaki, S Goto… - Cancer …, 2021 - Wiley Online Library
Chimeric antigen receptor (CAR)‐T cell therapy has shown salient efficacy in cancer
immunotherapy, particularly in the treatment of B cell malignancies. However, the efficacy of …
immunotherapy, particularly in the treatment of B cell malignancies. However, the efficacy of …
[HTML][HTML] Microwave-Assisted Synthesis of (Piperidin-1-yl) quinolin-3-yl) methylene) hydrazinecarbothioamides as Potent Inhibitors of Cholinesterases: A Biochemical …
Alzheimer's disease (AD), a progressive neurodegenerative disorder, characterized by
central cognitive dysfunction, memory loss, and intellectual decline poses a major public …
central cognitive dysfunction, memory loss, and intellectual decline poses a major public …
ALK inhibitor-induced bradycardia: a systematic-review and meta-analysis
Abstract Introduction Anaplastic Lymphoma Kinase (ALK) inhibitors have revolutionized the
treatment of advanced ALK-positive non-small cell lung cancer (NSCLC), improving …
treatment of advanced ALK-positive non-small cell lung cancer (NSCLC), improving …
Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases
T Naito, H Shiraishi, Y Fujiwara - Japanese Journal of Clinical …, 2021 - academic.oup.com
Major issues in anaplastic lymphoma kinase-positive non-small cell lung carcinoma are
acquired resistance against anaplastic lymphoma kinase inhibitors and control of central …
acquired resistance against anaplastic lymphoma kinase inhibitors and control of central …
[HTML][HTML] Silencing of CASC8 inhibits non-small cell lung cancer cells function and promotes sensitivity to osimertinib via FOXM1
X Jiang, J Guan, XU Yitong, H Ren, J Jiang… - Journal of …, 2021 - ncbi.nlm.nih.gov
In a meta-analysis, the long noncoding RNA cancer susceptibility candidate 8 (CASC8) was
found to be a cancer susceptibility gene closely related to lung cancer, but its functions in …
found to be a cancer susceptibility gene closely related to lung cancer, but its functions in …
[HTML][HTML] Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
S Kato, R Okamura, JJ Adashek, N Khalid, S Lee… - JCI insight, 2021 - ncbi.nlm.nih.gov
BACKGROUND Although CDK4/6 inhibitors are an established treatment for hormone
receptor–positive, HER2-negative metastatic breast cancers, their benefit in other …
receptor–positive, HER2-negative metastatic breast cancers, their benefit in other …
[HTML][HTML] Brain metastases: increasingly precision medicine—a narrative review
MJ McKay - Annals of Translational Medicine, 2021 - ncbi.nlm.nih.gov
Background Brain metastases are the commonest neurological manifestation of cancer and
a major cause of morbidity in cancer patients. Brain metastases are increasing in frequency …
a major cause of morbidity in cancer patients. Brain metastases are increasing in frequency …
[HTML][HTML] Selective inhibitor of the c-Met receptor tyrosine kinase in advanced hepatocellular carcinoma: no beneficial effect with the use of tivantinib?
S Zhao, W Wu, H Jiang, L Ma, C Pan, C Jin… - Frontiers in …, 2021 - frontiersin.org
Advanced hepatocellular carcinoma (HCC) remains a formidable health challenge
worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The …
worldwide, with a 5-year survival rate of 2.4% in patients with distant metastases. The …
[HTML][HTML] ALK rearrangement–positive pancreatic cancer with brain metastasis has remarkable response to ALK inhibitors: A case report
K Ou, X Liu, W Li, Y Yang, J Ying, L Yang - Frontiers in Oncology, 2021 - frontiersin.org
Patients with metastatic pancreatic cancer typically have poor prognosis due to the limited
effectiveness of existing treatment options. ALK rearrangement–positive is rare in pancreatic …
effectiveness of existing treatment options. ALK rearrangement–positive is rare in pancreatic …
[HTML][HTML] TRK inhibitors: tissue-agnostic anti-cancer drugs
SY Han - Pharmaceuticals, 2021 - mdpi.com
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have
been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and …
been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and …